Contributor Disclosures for Neuroimaging in Neurocysticercosis
Role Name Disclosure Details
Author Arturo Carpio, MD, Director of Epilepsy Center, Professor, Department of Neurology, University of Cuenca School of Medicine, Ecuador Nothing to discloseDetails
Coauthor Jorge Ugalde, MD, Chief, Department of Pathology, Sociedad De Lucha Contra El Cancer De Ecuador En Guayaquil Nothing to discloseDetails
Coauthor Nicholas Y Lorenzo, MD, Chief Editor, eMedicine Neurology; Consulting Staff, Neurology Specialists and Consultants Nothing to discloseDetails
Medical Editor Joseph F Hulihan, MD, Vice President, Medical Affairs, Ortho-McNeil Janssen Scientific Affairs, LLC Johnson & Johnson
Johnson & Johnson
Details
Pharmacy Editor Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine Nothing to discloseDetails
Managing Editor Florian P Thomas, MD, MA, PhD, Drmed, Director, Spinal Cord Injury Unit, St Louis Veterans Affairs Medical Center; Associate Program Director, Associate Professor, Departments of Neurology, Molecular Virology, and Molecular Microbiology and Immunology, St Louis University School of Medicine Nothing to discloseDetails
CME Editor Matthew J Baker, MD, Consulting Staff, Collier Neurologic Specialists, Naples Community Hospital Nothing to discloseDetails
Chief Editor Helmi L Lutsep, MD, Associate Professor, Department of Neurology, Oregon Health and Science University; Associate Director, Oregon Stroke Center Co-Axia
Talecris
AGA Medical
Boehringer Ingelheim
Boston Scientific
Details









Contributor:
Contributor Disclosure:
Arturo Carpio, Author  The contributor discloses no conflict of interest. 









Contributor Disclosure


Contributor:
Contributor Disclosure:
Jorge Ugalde, Coauthor  The contributor discloses no conflict of interest. 






 

CONTRIBUTOR DISCLOSURE FORM


Contributor Name:
Nicholas Y Lorenzo

 DECLARATION STATEMENT
I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
COMMERCIAL INTEREST
(Name of Organization)
Self
Spouse/
Partner
NATURE OF RELEVANT FINANCIAL RELATIONSHIP
What was received?*
For what role?**

Off label or investigational use of medication






 

CONTRIBUTOR DISCLOSURE FORM


Contributor Name:
Joseph F Hulihan

 DECLARATION STATEMENT
I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
COMMERCIAL INTEREST
(Name of Organization)
Self
Spouse/
Partner
NATURE OF RELEVANT FINANCIAL RELATIONSHIP
What was received?*
For what role?**

Johnson & Johnson
SalaryEmployment 
Johnson & Johnson
StockEmployment 
Off label or investigational use of medication
None






 

CONTRIBUTOR DISCLOSURE FORM


Contributor Name:
Francisco Talavera

 DECLARATION STATEMENT
I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
COMMERCIAL INTEREST
(Name of Organization)
Self
Spouse/
Partner
NATURE OF RELEVANT FINANCIAL RELATIONSHIP
What was received?*
For what role?**

Off label or investigational use of medication






 

CONTRIBUTOR DISCLOSURE FORM


Contributor Name:
Florian P Thomas

 DECLARATION STATEMENT
I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
COMMERCIAL INTEREST
(Name of Organization)
Self
Spouse/
Partner
NATURE OF RELEVANT FINANCIAL RELATIONSHIP
What was received?*
For what role?**

Off label or investigational use of medication









Contributor Disclosure


Contributor:
Contributor Disclosure:
Matthew J Baker, CME Editor  The contributor discloses no conflict of interest. 






 

CONTRIBUTOR DISCLOSURE FORM


Contributor Name:
Helmi L Lutsep

 DECLARATION STATEMENT
I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
COMMERCIAL INTEREST
(Name of Organization)
Self
Spouse/
Partner
NATURE OF RELEVANT FINANCIAL RELATIONSHIP
What was received?*
For what role?**

Co-Axia
Consulting feeReview panel membership 
Talecris
Consulting feeReview panel membership 
AGA Medical
Consulting feeReview panel membership 
Boehringer Ingelheim
HonorariaSpeaking and teaching 
Boston Scientific
HonorariaSpeaking and teaching 
Off label or investigational use of medication
As part of clinical trials that are reviewed by the IRB